TLR7 and systemic lupus erythematosus: These findings demonstrate the successful development of specific inhibitory anti-human TLR7 mAbs capable of inhibiting TLR7-mediated signaling, thereby offering potential therapeutic tools for targeting TLR7 in SLE.